Structure of Galunisertib
CAS No.: 700874-72-2
*Storage: {[sel_prStorage]}
*Shipping: {[sel_prShipping]}
The BI-3802 was designed by Boehringer Ingelheim and could be obtained free of charge through the Boehringer Ingelheim open innovation portal opnMe.com, associated with its negative control.
LY2157299 is a potent TGFβ receptor I (TβRI) inhibitor with IC50 of 56 nM in a cell-free assay.
Synonyms: LY2157299
4.5
*For Research Use Only !
Change View
Size | Price | VIP Price | US Stock |
Global Stock |
In Stock | ||
{[ item.pr_size ]} |
Inquiry
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.discount_usd) ]} {[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]} |
Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]} | Inquiry {[ item.pr_usastock ]} In Stock Inquiry - | {[ item.pr_chinastock ]} {[ item.pr_remark ]} In Stock 1-2 weeks - Inquiry - | Login | - + | Inquiry |
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days
1-2weeks
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price, item.pr_usd) ]}
Inquiry
{[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price, item.vip_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price, item.pr_usd) ]}
In Stock
- +
Please Login or Create an Account to: See VIP prices and availability
US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
Search for reports by entering the product batch number.
Batch number can be found on the product's label following the word 'Batch'.
CAS No. : | 700874-72-2 |
Formula : | C22H19N5O |
M.W : | 369.42 |
SMILES Code : | O=C(C1=CC=C2N=CC=C(C3=C(CCC4)N4N=C3C5=NC(C)=CC=C5)C2=C1)N |
Synonyms : |
LY2157299
|
MDL No. : | MFCD12923319 |
InChI Key : | IVRXNBXKWIJUQB-UHFFFAOYSA-N |
Pubchem ID : | 10090485 |
GHS Pictogram: |
![]() |
Signal Word: | Warning |
Hazard Statements: | H302-H315-H319-H332-H335 |
Precautionary Statements: | P261-P280-P305+P351+P338 |
Target |
|
In Vitro:
Concentration | Treated Time | Description | References |
human naïve CD4+ T cells | 10 µg/ml | 5 days | Galunisertib potently suppressed the differentiation of PD-1+CXCR5+ cells induced by Activin A | PMC4955732 |
HLE cells | 10 µM | 48 h | Galunisertib significantly reduced the expression of CD44 and THY1 in HLE and HLF cells, indicating that Galunisertib modulates the stemness phenotype of HCC cells by inhibiting the TGF-β signaling pathway. | PMC5841307 |
HLF cells | 10 µM | 48 h | Galunisertib significantly reduced the expression of CD44 and THY1 in HLE and HLF cells, indicating that Galunisertib modulates the stemness phenotype of HCC cells by inhibiting the TGF-β signaling pathway. | PMC5841307 |
HLF cells | 10 μM | 2 h and 48 h | To study the effect of Galunisertib on TGF-β1-induced gene expression, results showed that Galunisertib inhibited TGF-β1-induced gene upregulation. | PMC5386488 |
HepG2 cells | 10 μM | 2 h and 24 h | To study the effect of Galunisertib on TGF-β1-induced gene expression in HepG2 cells, results showed that Galunisertib had different effects on gene expression at different time points. | PMC5386488 |
HLE cells | 10 μM | 2 h and 24 h | To study the effect of Galunisertib on TGF-β1-induced gene expression in HLE cells, results showed that Galunisertib had different effects on gene expression at different time points. | PMC5386488 |
AGS cells | 5 µM | 8 h | Inhibition of TGF-β1 signaling pathway, reversal of EMT activation | PMC11568101 |
SGC-7901 cells | 5 µM | 8 h | Inhibition of TGF-β1 signaling pathway, reversal of EMT activation | PMC11568101 |
Panc1 | 10μM | 48 h | To evaluate the effect of chemotherapeutic agents on tumor cell immunogenicity, results showed that Gemcitabine significantly enhanced the expression of PD-L1, PD-L2, CTLA-4, HLA-A,B,C, and CD86 | PMC7777391 |
hPSC | 10μM | 48 h | To evaluate the effect of Galunisertib on immunomodulatory proteins in hPSC cells, results showed that Galunisertib significantly inhibited the induction of immunomodulatory proteins by Panc1-GR conditioned media | PMC7777391 |
HepG2 cells | 10 µM | 48 h | Galunisertib significantly inhibited the TGFβ1-induced phosphorylation of Smad2 and Smad3, indicating that the 3D liver scaffolds can be used as a drug screening platform. | PMC7017194 |
In Vivo:
Administration | Dosage | Frequency | Description | References |
BALB/c nude mice | subcutaneous tumor model | intraperitoneal injection | 300 µg/mouse | every 5 days for 3 weeks | Galunisertib treatment significantly reduced the volume and weight of subcutaneous tumors | PMC11568101 |
Mice | SMAD4-deficient colorectal cancer model | Oral | 75 mg/kg | Once daily for 7 days | Galunisertib inhibited the metastasis rate of SMAD4-deficient CRC cells and significantly reduced the proportion of intratumoral G-MDSCs. | PMC11365421 |
Nude mice | Subcutaneous xenograft model | Oral | 800 mg/kg | Once daily for an appropriate duration | Galunisertib treatment rescued the increased tumor growth and lung metastasis caused by HOOK1 knockdown, thereby prolonging the survival of tumor-bearing nude mice | PMC10265082 |
Mice | KC and KCT mouse models | Intraperitoneal injection | 75mg/kg | Twice weekly for four months | To evaluate the effect of combined Galunisertib and anti-PD-1 therapy on pancreatic cancer, results showed that in the setting of TGFβ signaling deficiency, the combination therapy significantly enhanced CD8+ T-cell response and reduced tumor burden | PMC7777391 |
Clinical Trial:
NCT Number | Conditions | Phases | Recruitment | Completion Date | Locations |
NCT03206177 | Carcinosarcoma, Ovarian | Phase 1 | Recruiting | June 1, 2022 | United States, Oklahoma ... More >> University of Oklahoma Health Sciences Center Recruiting Oklahoma City, Oklahoma, United States, 73104 Contact: Kathleen Moore, MD Less << |
NCT01373164 | Neoplasms Neo... More >>plasm Metastasis Pancreatic Cancer Less << | Phase 1 Phase 2 | Completed | - | United States, Florida ... More >> Florida Hospital Tampa HPG and Foregut Surgery Tampa, Florida, United States, 33613 United States, Illinois Ingalls Memorial Hospital Harvey, Illinois, United States, 60426 United States, Washington Seattle Cancer Care Alliance Seattle, Washington, United States, 98109 Belgium For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Brussel, Belgium, 1000 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Liège, Belgium, 4000 France For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Besancon, France, 25030 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Clermont-Ferrand, France, 63003 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Marseille, France, 13273 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Montbéliard, France, 25250 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Paris, France, 75674 Germany For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Frankfurt, Germany, 60596 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Friedrichshafen, Germany, 88045 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Leipzig, Germany, 04103 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Marburg, Germany, 35043 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Munich, Germany, 81925 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Mönchengladbach, Germany, 41063 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Reutlingen, Germany, 72764 Italy For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Bergamo, Italy, 24128 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Bologna, Italy, 40138 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Verona, Italy, 37134 Spain For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Barcelona, Spain, 08035 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Madrid, Spain, 28033 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Pozuelo De Alarcon, Spain, 28223 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Sevilla, Spain, 41013 Less << |
NCT01373164 | - | Completed | - | - | |
NCT01682187 | Glioma | Phase 1 | Active, not recruiting | May 1, 2019 | United States, Maryland ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Baltimore, Maryland, United States Spain For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Barcelona, Spain For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Madrid, Spain For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Sevilla, Spain Less << |
NCT01220271 | Glioma | Phase 1 Phase 2 | Completed | - | United States, California ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. La Jolla, California, United States, 92093 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. San Francisco, California, United States, 94143 United States, Florida For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Tampa, Florida, United States, 33612 United States, Illinois For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Chicago, Illinois, United States, 60611 United States, Indiana For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Indianapolis, Indiana, United States, 46202 United States, North Carolina For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Durham, North Carolina, United States, 27710 Germany For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Frankfurt, Germany, 60596 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Heidelberg, Germany, 69120 Spain For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Barcelona, Spain, 08035 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Madrid, Spain, 28041 Less << |
NCT01246986 | Carcinoma, Hepatocellular | Phase 2 | Active, not recruiting | December 3, 2018 | - |
NCT01582269 | Glioblastoma | Phase 2 | Active, not recruiting | December 31, 2019 | - |
NCT02538471 | Metastatic Breast Cancer | Phase 2 | Active, not recruiting | August 2019 | United States, New York ... More >> Weill Cornell Medical College New York, New York, United States, 10065 Less << |
NCT02178358 | Hepatocellular Carcinoma | Phase 2 | Active, not recruiting | December 31, 2018 | China ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Beijing, China, 100036 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Bengbu, China, 233004 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Changchun, China, 130012 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Hangzhou, China, 310016 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Hefei, China, 230022 Hong Kong For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Hong Kong, Hong Kong For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Kowloon, Hong Kong Korea, Republic of For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Incheon, Korea, Republic of, 405-760 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Seoul, Korea, Republic of, 135 720 Taiwan For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Gwei Shan Township, Taiwan, 333 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Liouying/Tainan, Taiwan, 736 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Puzih City, Taiwan, 613 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Tainan, Taiwan, 70403 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Taipei, Taiwan, 11217 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Taoyuan, Taiwan, 33378 Thailand For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Bangkok, Thailand, 10330 Less << |
NCT02672475 | Estrogen Receptor Negative ... More >> HER2/Neu Negative Progesterone Receptor Negative Recurrent Breast Carcinoma Stage IV Breast Cancer Triple-Negative Breast Carcinoma Less << | Phase 1 | Recruiting | June 2021 | United States, Tennessee ... More >> Vanderbilt University/Ingram Cancer Center Recruiting Nashville, Tennessee, United States, 37232 Contact: G. VICC Clinical Trials Information Program 800-811-8480 Principal Investigator: Vandana G. Abramson, MD Less << |
NCT02008318 | Myelodysplastic Syndromes | Phase 2 Phase 3 | Completed | - | Germany ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Dresden, Germany, 01307 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Düsseldorf, Germany, 40479 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Jena, Germany, 07747 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Lübeck, Germany, 23562 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Ulm, Germany, 89081 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Westerstede, Germany, 26655 Italy For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Firenze, Italy, 50134 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Novara, Italy, 28100 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Rome, Italy, 00161 Spain For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Barcelona, Spain, 08035 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Madrid, Spain, 28050 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Oviedo, Spain, 33011 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Salamanca, Spain, 37007 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Valencia, Spain, 46026 Less << |
NCT03470350 | Colorectal Cancer Metastatic | PHASE1|PHASE2 | WITHDRAWN | 2020-06-01 | Antoni van Leeuwenhoek (NKI-AV... More >>L), Amsterdam, Noord-Holland, 1066 CX, Netherlands Less << |
NCT02734160 | Metastatic Pancreatic Cancer | Phase 1 | Active, not recruiting | June 17, 2019 | United States, Arizona ... More >> Honor Health Research Institute Scottsdale, Arizona, United States, 85258 United States, New York Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 United States, Tennessee Sarah Cannon Research Institute SCRI Nashville, Tennessee, United States, 37203 Tennessee Oncology PLLC Nashville, Tennessee, United States, 37203 France Gustave Roussy Villejuif Cedex, France, 94805 Italy Ospedale Policlinico Giambattista Rossi, Borgo Roma Verona, Italy, 37134 Korea, Republic of Samsung Medical Center Seoul, Korea, Korea, Republic of, 06351 Seoul National University Hospital Seoul, Korea, Republic of, 03080 Spain Hospital Universitari Vall d'Hebron Barcelona, Spain, 08035 Hospital Universitario 12 de Octubre Madrid, Spain, 28041 Hospital Madrid Norte Sanchinarro Madrid, Spain, 28050 Less << |
NCT02304419 | Neoplasm | PHASE1 | COMPLETED | 2025-08-16 | Memorial Sloan Kettering Cance... More >>r Center, New York City, New York, 10065, United States Less << |
NCT02452008 | Prostate Cancer | Phase 2 | Recruiting | July 2021 | United States, District of Col... More >>umbia Sibley Memorial Hospital Recruiting Washington, District of Columbia, United States, 20016 Contact: Janice Powers, RN 202-660-5772 jpower22@JHMI.EDU Principal Investigator: Channing Paller, MD United States, Illinois Northwestern University Recruiting Chicago, Illinois, United States, 60611 Contact: Maha Hussain, MD 312-908-5487 maha.hussain@northwestern.edu Principal Investigator: Maha Hussain, MD University of Chicago Recruiting Chicago, Illinois, United States, 60637 Contact: Russel Szmulewitz, MD 773-702-7609 rszmulew@medicine.bsd.uchicago.edu Contact: Kelly O'Connor 773-702-4653 koconnor@medicine.bsd.uchicago.edu Principal Investigator: Russel Szmulewitz, MD United States, Maryland Johns Hopkins University Recruiting Baltimore, Maryland, United States, 21205 Contact: Channing Paller, MD 410-614-6321 cpaller@JHMI.EDU Contact: Irina Rifkind, RN 410-502-2043 irifkin1@JHMI.EDU Principal Investigator: Channing Paller, MD Less << |
NCT02688712 | Rectal Adenocarcinoma | Phase 2 | Recruiting | June 2022 | United States, Oregon ... More >> Providence Cancer Center Recruiting Portland, Oregon, United States, 97213 Contact: Larissa Lundgren 503-215-2614 Larisa.Lundgren@providence.org Sub-Investigator: Walter J. Urba, M.D., Ph.D Sub-Investigator: Rachel Sanborn, MD Sub-Investigator: Todd Crocenzi, MD Sub-Investigator: Bernard Fox, Ph.D Sub-Investigator: Michael Gough, Ph.D. Sub-Investigator: Stephen Bader, MD Sub-Investigator: Alice Wang-Chesebro, MD Sub-Investigator: Matthew Solhjem, MD Sub-Investigator: Rui Li, MD, PhD Sub-Investigator: Rom Leidner, MD Sub-Investigator: Marka Crittenden, MD, PhD Sub-Investigator: Steven Seung, MD, PhD Sub-Investigator: Mark Whiteford, MD Sub-Investigator: David Page, MD Sub-Investigator: John Godwin, MD Less << |
NCT01746004 | Healthy Volunteers | Phase 1 | Completed | - | United States, Wisconsin ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Madison, Wisconsin, United States, 53704 Less << |
NCT02752919 | Healthy | PHASE1 | COMPLETED | 2025-06-16 | For additional information reg... More >>arding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Leeds, West Yorkshire, United Kingdom Less << |
NCT01965808 | Healthy Volunteers | PHASE1 | COMPLETED | 2025-12-13 | For additional information reg... More >>arding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Daytona Beach, Florida, 31227, United States Less << |
NCT01722825 | Neoplasms|Neoplasm Metastasis | PHASE1 | COMPLETED | 2025-06-14 | For additional information reg... More >>arding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559 ) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Tokyo, 104-0045, Japan Less << |
NCT02154646 | Pancreatic Neoplasms | Phase 1 | Completed | - | Japan ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Chiba, Japan, 277 8577 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Tokyo, Japan, 104-0045 Less << |
NCT02240433 | Hepatocellular Carcinoma | Phase 1 | Active, not recruiting | February 11, 2019 | Japan ... More >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Chiba, Japan, 277 8577 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Kanagawa, Japan, 241-8515 For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. Suita-shi, Japan, 565-0871 Less << |
NCT02423343 | Solid Tumor N... More >>on-Small Cell Lung Cancer Recurrent Hepatocellular Carcinoma Recurrent Less << | Phase 1 Phase 2 | Recruiting | December 20, 2019 | United States, Alabama ... More >> University of Alabama at Birmingham Medical Center Recruiting Birmingham, Alabama, United States, 35294 Contact 2059961403 Principal Investigator: Mansoor Noorali Saleh United States, California University of California - San Diego Recruiting La Jolla, California, United States, 92093 Contact 858-534-3804 Principal Investigator: Sandip Patel United States, Florida H Lee Moffitt Cancer Center Recruiting Tampa, Florida, United States, 33612-9497 Contact 813-745-2677 Principal Investigator: Scott J Antonia United States, Massachusetts Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact 617-632-2166 Principal Investigator: David A Reardon United States, Texas University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact 713-563-2169 Principal Investigator: David S Hong Spain Hospital Universitari Vall d'Hebron Recruiting Barcelona, Spain, 08035 Contact 34932746085 Principal Investigator: Elena Garralda Cabanas Institut Catala d'Oncologia Recruiting Barcelona, Spain, 08907 Contact 34932607744 Principal Investigator: Ernest Nadal Alforja Hospital Universitario 12 de Octubre Recruiting Madrid, Spain, 28041 Contact 34913908626 Principal Investigator: Santiago Ponce Aix Hospital Regional Universitario de Málaga Recruiting Malaga, Spain, 29010 Contact 34951030543 Principal Investigator: Manuel Cobo Dols Less << |
NCT02906397 | ADVANCED HEPATOCELLULAR CARCIN... More >>OMA (HCC) Less << | Phase 1 | Active, not recruiting | January 2019 | United States, Pennsylvania ... More >> Abramson Cancer Center of the University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 Less << |
Bio Calculators | ||||
Preparing Stock Solutions | ![]() |
1mg | 5mg | 10mg |
1 mM 5 mM 10 mM |
2.71mL 0.54mL 0.27mL |
13.53mL 2.71mL 1.35mL |
27.07mL 5.41mL 2.71mL |
|
Dissolving Methods |
in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:
|